Safety, acceptability, and pharmacokinetics of a monoclonal antibody-based vaginal multipurpose prevention film (MB66): A Phase I randomized trial.

PLoS Med · 2021 · PMC7857576 · PMID 33534791

Europe PMC DOI

hedged sentence

0.0520

closest p · 1.0× alpha

0.0520

boldest claim

The sentences

did not quite reach significancep = 0.052so close (0.05 < p ≤ 0.1)

HSV-2 neutralization In Segment A, all CVL samples collected 24 hours after insertion of a single film exhibited 100% neutralization of HSV-2; however, the omnibus F test p -value for the ANOVA for HSV-2 neutralization did not quite reach significance ( p = 0.052) due to small sample size and neutralization activity in some of the baseline samples ( Fig 5B and S4 Fig ).

also in 350 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.